Merck, Sichuan Kelun enter cancer collaboration, with milestone payments up to $9.3 billion


Merck & Co. Inc. MRK, +0.12% said Thursday that it entered into an agreement with Sichuan Kelun Pharmaceutical Co. Ltd. 002422, +10.00% to develop seven new cancer therapies. Merck will pay the Chinse biotech an upfront payment of $175 million, with milestone payments worth up to $9.3 billion. Merck will also make an equity investment in the company. Merck’s stock is up 44.7% so far this year, while the S&P 500 SPX, -1.45% is down 18.6%.

This article was originally published by Read the original article here.

Previous articleThe Moneyist: ‘We can practically finish each other’s sentences’: I’m getting married in 2023. I want a prenup. She wants to merge our finances. What’s my next move?
Next articleU.S. initial jobless claims rise to 216,000 in latest week


Please enter your comment!
Please enter your name here